Please wait while the formulary information is being retrieved.
ERBITUX (CETUXIMAB)
- Squamous cell carcinoma of head and neck
- Wild-type KRAS colorectal cancer
100 mg/50 mL intravenous solution
- Infuse 250 mg/m2 over 60 minute(s) by intravenous route once weekly (maximum infusion rate 10 mg/min)
200 mg/100 mL intravenous solution
- Infuse 250 mg/m2 over 60 minute(s) by intravenous route once weekly (maximum infusion rate 10 mg/min)
Squamous cell carcinoma of head and neck
- Infuse 250 mg/m2 over 60 minute(s) by intravenous route once weekly (maximum infusion rate 10 mg/min)
- Infuse 200 mg/m2 over 60 minute(s) by intravenous route once weekly (maximum infusion rate 10 mg/min)
- Infuse 150 mg/m2 over 60 minute(s) by intravenous route once weekly (maximum infusion rate 10 mg/min)
Wild-type KRAS colorectal cancer
- Infuse 250 mg/m2 over 60 minute(s) by intravenous route once weekly (maximum infusion rate 10 mg/min)
- Infuse 200 mg/m2 over 60 minute(s) by intravenous route once weekly (maximum infusion rate 10 mg/min)
- Infuse 150 mg/m2 over 60 minute(s) by intravenous route once weekly (maximum infusion rate 10 mg/min)
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Acneiform eruption
- Bacterial skin and skin structure infection
- Chronic heart failure
- Coronary artery disease
- Interstitial pneumonitis
- Pregnancy
- Pulmonary fibrosis
Severe
Moderate
- Hypocalcemia
- Hypokalemia
- Hypomagnesemia
ERBITUX (CETUXIMAB)
- Squamous cell carcinoma of head and neck
- Wild-type KRAS colorectal cancer
- Abnormal hepatic function tests
- Anemia
- Dizziness
- Dyspnea
- Hypertension
- Hypomagnesemia
- Increased alanine transaminase
- Increased aspartate transaminase
- Infection
- Radiodermatitis
- Skin rash
- Acneiform eruption
- Alopecia
- Anorexia
- Back pain
- Conjunctivitis
- Constipation
- Cough
- Depression
- Diarrhea
- Dyspepsia
- Fever
- General weakness
- Headache disorder
- Insomnia
- Malaise
- Nail disorders
- Nausea
- Pain
- Peripheral sensory neuropathy
- Pharyngitis
- Pruritus of skin
- Stomatitis
- Vomiting
- Weight loss
- Xerostomia
More Frequent
Severe
Less Severe
- Anaphylaxis
- Dehydration
- Dysphagia
- Hypersensitivity drug reaction
- Hypocalcemia
- Hypokalemia
- Leukopenia
- Pulmonary thromboembolism
- Renal failure
- Skin fissure
- Blepharitis
- Cheilitis
- Chills
- Dry skin
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Angioedema
- Bacterial sepsis
- Bronchospastic pulmonary disease
- Bullous dermatitis
- Cardiac arrest
- Cellulitis
- Dermatitis due to sunlight
- Hypotension
- Interstitial lung disease
- Keratitis
- Non-infective meningitis
- Radiation recall syndrome
- Shock
- Stevens-johnson syndrome
- Stridor
- Toxic epidermal necrolysis
- Unconsciousness
- Urticaria
Less Severe
- Hirsutism
- Hoarseness
- Injection site sequelae
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Cetuximab
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Cetuximab
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Cetuximab
Discontinue breastfeeding during treatment and for 60 days after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Discontinue breastfeeding during treatment and for 60 days after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Severe (sometimes fatal) reactions have occurred in people while receiving cetuximab. Your risk may be higher if you have a history of tick bites or have a severe allergic reaction to meat (such as beef, pork). Before receiving cetuximab, tell your doctor if you have either of these conditions.<br /><br />Your doctor will carefully monitor you during and for at least one hour after your infusion. Tell your doctor right away if you have shortness of breath, hoarseness, itching, or dizziness. Your doctor may stop treatment with this medication if you have a severe reaction.<br /><br /> Rare deaths due to heart problems (cardiopulmonary arrest) or sudden death have occurred in people with head and neck cancer treated with cetuximab. Before starting treatment with this medication, tell your doctor if you have a history of heart disease (such as heart failure, irregular heartbeat, previous heart attack). Get medical help right away if you develop chest/jaw/left arm pain, shortness of breath, or unusual sweating. Your doctor will order certain blood tests (including magnesium, calcium, and potassium) during and after your treatment to monitor and help decrease your risk for heart problems.
| Squamous cell carcinoma of head and neck | |
| C44.02 | Squamous cell carcinoma of skin of lip |
| C44.12 | Squamous cell carcinoma of skin of eyelid, including canthus |
| C44.121 | Squamous cell carcinoma of skin of unspecified eyelid, including canthus |
| C44.122 | Squamous cell carcinoma of skin of right eyelid, including canthus |
| C44.1221 | Squamous cell carcinoma of skin of right upper eyelid, including canthus |
| C44.1222 | Squamous cell carcinoma of skin of right lower eyelid, including canthus |
| C44.129 | Squamous cell carcinoma of skin of left eyelid, including canthus |
| C44.1291 | Squamous cell carcinoma of skin of left upper eyelid, including canthus |
| C44.1292 | Squamous cell carcinoma of skin of left lower eyelid, including canthus |
| C44.22 | Squamous cell carcinoma of skin of ear and external auricular canal |
| C44.221 | Squamous cell carcinoma of skin of unspecified ear and external auricular canal |
| C44.222 | Squamous cell carcinoma of skin of right ear and external auricular canal |
| C44.229 | Squamous cell carcinoma of skin of left ear and external auricular canal |
| C44.32 | Squamous cell carcinoma of skin of other and unspecified parts of face |
| C44.320 | Squamous cell carcinoma of skin of unspecified parts of face |
| C44.321 | Squamous cell carcinoma of skin of nose |
| C44.329 | Squamous cell carcinoma of skin of other parts of face |
| C44.42 | Squamous cell carcinoma of skin of scalp and neck |
| Wild-type KRAS colorectal cancer | |
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| 0-9 | A-Z |
|---|---|
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C44.02 | Squamous cell carcinoma of skin of lip |
| C44.12 | Squamous cell carcinoma of skin of eyelid, including canthus |
| C44.121 | Squamous cell carcinoma of skin of unspecified eyelid, including canthus |
| C44.122 | Squamous cell carcinoma of skin of right eyelid, including canthus |
| C44.1221 | Squamous cell carcinoma of skin of right upper eyelid, including canthus |
| C44.1222 | Squamous cell carcinoma of skin of right lower eyelid, including canthus |
| C44.129 | Squamous cell carcinoma of skin of left eyelid, including canthus |
| C44.1291 | Squamous cell carcinoma of skin of left upper eyelid, including canthus |
| C44.1292 | Squamous cell carcinoma of skin of left lower eyelid, including canthus |
| C44.22 | Squamous cell carcinoma of skin of ear and external auricular canal |
| C44.221 | Squamous cell carcinoma of skin of unspecified ear and external auricular canal |
| C44.222 | Squamous cell carcinoma of skin of right ear and external auricular canal |
| C44.229 | Squamous cell carcinoma of skin of left ear and external auricular canal |
| C44.32 | Squamous cell carcinoma of skin of other and unspecified parts of face |
| C44.320 | Squamous cell carcinoma of skin of unspecified parts of face |
| C44.321 | Squamous cell carcinoma of skin of nose |
| C44.329 | Squamous cell carcinoma of skin of other parts of face |
| C44.42 | Squamous cell carcinoma of skin of scalp and neck |
Formulary Reference Tool